Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

NCT00238446 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Interventions

DRUG: EC-MPS

Sponsor

Novartis Pharmaceuticals